Autoimmune Hepatitis: Factors Involved in Initiation and Methods of Diagnosis and Treatment

被引:3
|
作者
Lauletta, Gianfranco [1 ]
Russi, Sabino [1 ]
Pavone, Fabio [1 ]
Marzullo, Andrea [2 ]
Tampoia, Marilina [3 ]
Sansonno, Domenico [1 ]
Dammacco, Franco [1 ]
机构
[1] Univ Bari, Med Sch, Dept Biomed Sci & Human Oncol, Piazza G Cesare 11, I-70124 Bari, Italy
[2] Univ Bari, Med Sch, Pathol Sect, Dept Emergency & Organ Transplantat, Bari, Italy
[3] Univ Hosp, Lab Clin Pathol, Bari, Italy
关键词
autoimmune hepatitis; anti-nuclear antibodies; anti-smooth muscle antibodies; anti-LKM antibodies; corticosteroids; immunosuppressive drugs; REGULATORY T-CELLS; MAJOR HISTOCOMPATIBILITY COMPLEX; CHRONIC ACTIVE HEPATITIS; KIDNEY MICROSOMAL AUTOANTIBODIES; PRIMARY SCLEROSING CHOLANGITIS; EPSTEIN-BARR-VIRUS; TREATMENT RESPONSE; CLINICAL CHARACTERISTICS; MYCOPHENOLATE-MOFETIL; INFLAMMATORY-BOWEL;
D O I
10.1615/CritRevImmunol.2017017868
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Autoimmune hepatitis is an acute or mostly chronic liver disease that can affect both adults and children and has a clear prevalence for the female sex. A definite etiology has not been established, but it is known that genetic predisposing profiles and exogenous trigger factors are involved. The main diagnostic criteria include typical histological features, the occurrence of serum auto-antibodies, and increased levels of transaminases and gamma-globulins. Instances of autoimmune hepatitis sharing features with other autoimmune liver diseases have also been observed. An imbalance of the immune system with persistent activation of effector T cells has been emphasized to account for the sustained liver injury. Clinical manifestations are variable both at presentation and throughout the course of the disease, ranging from an asymptomatic state or the occurrence of non-specific symptoms to the features of end-stage liver disease such as jaundice, ascites, and gastrointestinal bleeding. A clinical and biochemical remission is achieved in at least 80% of patients receiving corticosteroids with or without the addition of azathioprine. Alternative therapeutic schedules have been proposed for unresponsive and intolerant patients. Given that relapse often occurs after therapy withdrawal, maintenance treatment is usually required.
引用
收藏
页码:407 / 428
页数:22
相关论文
共 50 条
  • [31] Diagnosis and Management of Autoimmune Hepatitis
    Manns, Michael P.
    Czaja, Albert J.
    Gorham, James D.
    Krawitt, Edward L.
    Mieli-Vergani, Giorgina
    Vergani, Diego
    Vierling, John M.
    HEPATOLOGY, 2010, 51 (06) : 2193 - 2213
  • [32] Autoimmune hepatitis: Immunological diagnosis
    Brahim, Imane
    Brahim, Ikram
    Hazime, Raja
    Admou, Brahim
    PRESSE MEDICALE, 2017, 46 (11): : 1008 - 1019
  • [33] DIAGNOSIS AND THERAPY OF AUTOIMMUNE HEPATITIS
    HEINTGES, T
    MOHR, L
    NIEDERAU, C
    STROHMEYER, G
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 1995, 33 (08): : 462 - 467
  • [34] Diagnosis and Therapy of Autoimmune Hepatitis
    Granito, Alessandro
    Muratori, Paolo
    Ferri, Silvia
    Pappas, Georgios
    Quarneti, Chiara
    Lenzi, Marco
    Bianchi, Francesco B.
    Muratori, Luigi
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2009, 9 (07) : 847 - 860
  • [35] Diagnosis and management of autoimmune hepatitis
    Muratori, Luigi
    Lohse, Ansgar W.
    Lenzi, Marco
    BMJ-BRITISH MEDICAL JOURNAL, 2023, 380
  • [36] Diagnosis and Management of Autoimmune Hepatitis
    Czaja, Albert J.
    CLINICS IN LIVER DISEASE, 2015, 19 (01) : 57 - 79
  • [37] Treatment of autoimmune hepatitis
    Rambusch, EG
    Manns, MP
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1996, 121 (49) : 1539 - 1542
  • [38] Treatment of autoimmune hepatitis
    Czaja, AJ
    SEMINARS IN LIVER DISEASE, 2002, 22 (04) : 365 - 377
  • [39] The Treatment of Autoimmune Hepatitis
    Malnick, Stephen
    Duek, Gabriel
    Melzer, Ehud
    Basevitz, Alon
    CURRENT CLINICAL PHARMACOLOGY, 2012, 7 (04): : 318 - 327
  • [40] Treatment of Autoimmune Hepatitis
    Goel, Aparna
    Kwo, Paul
    CLINICS IN LIVER DISEASE, 2024, 28 (01) : 51 - 61